Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2023]

Author(s):

1. Irem Oner: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

2. Alper Turkel: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

3. Cengiz Karacin: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

4. Erdogan Seyran: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

5. Pinar Kubilay Tolunay: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

6. Omur Berna Cakmak Oksuzoglu: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey

Abstract:

Objective: To evaluate the e ect of complete pathological response (pCR) on prognosis in patients with axillary lymph node-positive triple-negative breast cancer (TNBC) and the e ciency of adjuvant capecitabine. Study Design: Analytical study. Place and Duration of the Study:University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, between March 2015 and December 2021. Methodology: The study included 92 patients with TNBC with enlarged axillary lymph nodes and treated with neoadjuvant chemotherapy. The patients were classi ed as those with and without postoperative pCR and compared in terms of survival. Subsequently, the patients who did not achieve pCR were classi ed as receiving and not receiving adjuvant capecitabine and were compared for DFS (disease-free survival) and OS (overall survival). Parameters that showed statistical signi cance were re-evaluated with Cox regression analysis. Results: The 5-year DFS rate was 84.3% in those who achieved pCR, while it was 55.1% in those who did not (p=0.026). The 5-year OS rate was 82.8% in the pCR arm, while it was 51.0% in the non-pCR arm (p=0.070). The 5-year DFS rate was 66.3% in adjuvant capecitabine-receiving patients, while it was 40.8% in the non-capecitabine arm (HR=0.40, p=0.031). The 5-year OS rate was 68.9% in adjuvant capecitabine-receiving patients, while it was 29.6% in the non-capecitabine arm (HR= 0.40, p=0.062). Conclusion: Obtaining pCR following NAC in a locally advanced TNBC is an independent prognostic marker for DFS and OS. In the presence of residual disease, improvement in DFS and OS with adjuvant capecitabine was demonstrated by the real-life data.

Page(s): 1012-1018

DOI: 10.29271/jcpsp.2023.09.1012

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 9, Year: 2023

Keywords:

survival , Neoadjuvant chemotherapy , triplenegative breast cancer , Capecitabine

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views